CytomX Therapeutics, Inc. (CTMX): Price and Financial Metrics


CytomX Therapeutics, Inc. (CTMX): $1.71

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CTMX POWR Grades

  • CTMX scores best on the Value dimension, with a Value rank ahead of 66.57% of US stocks.
  • CTMX's strongest trending metric is Growth; it's been moving up over the last 179 days.
  • CTMX ranks lowest in Momentum; there it ranks in the 4th percentile.

CTMX Stock Summary

  • Of note is the ratio of CYTOMX THERAPEUTICS INC's sales and general administrative expense to its total operating expenses; just 10.67% of US stocks have a lower such ratio.
  • The ratio of debt to operating expenses for CYTOMX THERAPEUTICS INC is higher than it is for about only 14.32% of US stocks.
  • The volatility of CYTOMX THERAPEUTICS INC's share price is greater than that of 87.3% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to CTMX, based on their financial statements, market capitalization, and price volatility, are EIGR, CLLS, SYRS, HUMA, and IKNA.
  • Visit CTMX's SEC page to see the company's official filings. To visit the company's web site, go to www.cytomx.com.

CTMX Valuation Summary

  • CTMX's EV/EBIT ratio is -0.4; this is 104.65% lower than that of the median Healthcare stock.
  • Over the past 87 months, CTMX's EV/EBIT ratio has gone up 15.4.

Below are key valuation metrics over time for CTMX.

Stock Date P/S P/B P/E EV/EBIT
CTMX 2022-11-25 1.7 4.2 -1.2 -0.4
CTMX 2022-11-23 1.6 4.2 -1.2 -0.4
CTMX 2022-11-22 1.8 4.4 -1.3 -0.5
CTMX 2022-11-21 1.6 4.0 -1.2 -0.3
CTMX 2022-11-18 1.6 4.0 -1.2 -0.3
CTMX 2022-11-17 1.5 3.7 -1.1 -0.3

CTMX Growth Metrics

    The year over year net income to common stockholders growth rate now stands at -51.61%.
  • Its 5 year revenue growth rate is now at 415.83%.
  • Its year over year revenue growth rate is now at 5.99%.
CTMX's revenue has moved up $57,572,000 over the prior 67 months.

The table below shows CTMX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 72.615 -136.442 -96.881
2022-03-31 70.738 -130.404 -91.94
2021-12-31 69.573 -119.031 -83.609
2021-09-30 66.219 -105.266 -72.082
2021-06-30 66.42 -100.244 -64.208
2021-03-31 66.74 25.056 -60.644

CTMX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CTMX has a Quality Grade of D, ranking ahead of 22.16% of graded US stocks.
  • CTMX's asset turnover comes in at 0.169 -- ranking 210th of 682 Pharmaceutical Products stocks.
  • JNJ, LEXX, and ORGS are the stocks whose asset turnover ratios are most correlated with CTMX.

The table below shows CTMX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.169 1 -0.872
2021-03-31 0.170 1 -0.944
2020-12-31 0.255 1 -0.424
2020-09-30 0.237 1 -0.610
2020-06-30 0.219 1 -0.636
2020-03-31 0.200 1 -0.554

CTMX Price Target

For more insight on analysts targets of CTMX, see our CTMX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $13.00 Average Broker Recommendation 1.5 (Moderate Buy)

CTMX Stock Price Chart Interactive Chart >

Price chart for CTMX

CTMX Price/Volume Stats

Current price $1.71 52-week high $6.97
Prev. close $1.71 52-week low $1.17
Day low $1.66 Volume 570,900
Day high $1.71 Avg. volume 1,282,317
50-day MA $1.44 Dividend yield N/A
200-day MA $1.92 Market Cap 113.00M

CytomX Therapeutics, Inc. (CTMX) Company Bio


CytomX Therapeutics develops a novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology. The company was founded in 2008 and is based in San Francisco, California.


CTMX Latest News Stream


Event/Time News Detail
Loading, please wait...

CTMX Latest Social Stream


Loading social stream, please wait...

View Full CTMX Social Stream

Latest CTMX News From Around the Web

Below are the latest news stories about CYTOMX THERAPEUTICS INC that investors may wish to consider to help them evaluate CTMX as an investment opportunity.

Biotech Stock Roundup: CTMX Surges on REGN's Deal, APLS Up on Regulatory Update

Updates from CTMX and APLS are the key highlights from the biotech sector during the past week.

Yahoo | November 23, 2022

CytomX Therapeutics (CTMX) Receives a Hold from H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor reiterated a Hold rating on CytomX Therapeutics (CTMX - Research Report) today. The company's shares closed yesterday at $1.60.According to TipRanks, Kapoor is a 2-star analyst with an average return of -1.9% and a 47.62% success rate. Kapoor covers the Healthcare sector, focusing on stocks such as CytomX Therapeutics, Rain Therapeutics, and Lyell Immunopharma.The word on The Street in general, suggests a Hold analyst consensus rating for CytomX Therapeutics with a $3.30 average price target, representing a 106.25% upside. In a report released yesterday, Mizuho Securities also maintained a Hold rating on the stock with a $4.00 price target.

Catie Powers on TipRanks | November 18, 2022

CytomX (CTMX) Stock Surges on Oncology Deal With Regeneron

CytomX (CTMX) gets a boost after its deal with Regeneron for the development of investigational next-generation bispecific immunotherapies.

Yahoo | November 18, 2022

Mizuho Securities Remains a Hold on CytomX Therapeutics (CTMX)

In a report released today, Mara Goldstein from Mizuho Securities maintained a Hold rating on CytomX Therapeutics (CTMX - Research Report), with a price target of $4.00. The company's shares closed yesterday at $1.21.Goldstein covers the Healthcare sector, focusing on stocks such as Incyte, Arcus Biosciences, and Adaptimmune Therapeutics. According to TipRanks, Goldstein has an average return of 0.7% and a 36.65% success rate on recommended stocks. In addition to Mizuho Securities, CytomX Therapeutics also received a Hold from BMO Capital's Etzer Darout in a report issued on November 14. However, on November 13, J.P. Morgan downgraded CytomX Therapeutics (NASDAQ: CTMX) to a Sell.

Christine Brown on TipRanks | November 17, 2022

Mullen (MULN) Stock Pops 4% on ELMS Funding News

Mullen (MULN) stock is on the move Thursday following news of the EV company acquiring funding for its purchase of ELMS assets.

William White on InvestorPlace | November 17, 2022

Read More 'CTMX' Stories Here

CTMX Price Returns

1-mo 36.80%
3-mo 17.12%
6-mo -1.72%
1-year -74.13%
3-year -73.73%
5-year -91.77%
YTD -60.51%
2021 -33.89%
2020 -21.18%
2019 -44.97%
2018 -28.47%
2017 92.08%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7156 seconds.